CGS 19755 (Selfotel): A Novel Neuroprotective Agent Against CNS Injury.

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Excitotoxicity is a key mechanism in cerebral injury, including ischemia and trauma.
• Glutamate neurotoxicity, mediated by N-methyl-D-aspartate (NMDA) receptors, plays a significant role in ischemic brain damage.
• NMDA receptor antagonists have emerged as potential therapeutic agents for neuroprotection.

Purpose of the Study:

• To review the role of excitotoxicity in cerebral injury.
• To discuss the development and efficacy of NMDA receptor antagonists for neuroprotection.
• To highlight the potential of newer competitive NMDA antagonists like selfotel in treating stroke and head trauma.

Main Methods:

• Literature review of studies on excitotoxicity and NMDA receptor antagonists.
• Analysis of findings related to competitive and noncompetitive NMDA antagonist efficacy.
• Examination of clinical trial data for selfotel in stroke and head trauma.

Main Results:

• NMDA receptor antagonists demonstrate neuroprotective effects against hypoxic-ischemic injury.
• Noncompetitive NMDA antagonists are lipophilic and achieve high brain concentrations systemically.
• Competitive NMDA antagonists, such as selfotel, provide neuroprotection against global/focal ischemia and trauma when administered systemically.

Conclusions:

• NMDA receptor antagonism is a viable strategy for mitigating excitotoxic brain damage.
• Selfotel (CGS 19755) shows promise as a systemically administered neuroprotective agent for stroke and head trauma.
• Ongoing clinical trials are evaluating the safety and efficacy of selfotel.